

# Giampaolo Perna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6303249/publications.pdf>

Version: 2024-02-01

199  
papers

6,194  
citations

61984  
43  
h-index

110387  
64  
g-index

203  
all docs

203  
docs citations

203  
times ranked

6690  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of illness remission in patients with Obsessive-Compulsive Disorder with supervised machine learning. Journal of Affective Disorders, 2022, 296, 117-125.	4.1	2
2	Predicting New-Onset Psychiatric Disorders Throughout the COVID-19 Pandemic: A Machine Learning Approach. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 233-246.	1.8	4
3	First-onset major depression during the COVID-19 pandemic: A predictive machine learning model. Journal of Affective Disorders, 2022, 310, 75-86.	4.1	6
4	No Sex Differences in Self-Reported Childhood Maltreatment in Major Depressive and Bipolar Disorders: A Retrospective Study. Brain Sciences, 2022, 12, 804.	2.3	2
5	Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting. Psychiatry Research, 2021, 295, 113556.	3.3	3
6	Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110208.	4.8	7
7	COVID-19 and panic disorder: clinical considerations for the most physical of mental disorders. Revista Brasileira De Psiquiatria, 2021, 43, 110-111.	1.7	6
8	Experimental Drugs for Panic Disorder: An Updated Systematic Review. Journal of Experimental Pharmacology, 2021, Volume 13, 441-459.	3.2	6
9	751 Heart Rate and Heart Rate Variability During Sleep As Biomarkers for Depression. Sleep, 2021, 44, A293-A293.	1.1	0
10	253 Better and faster automatic sleep staging with artificial intelligence. Sleep, 2021, 44, A102-A102.	1.1	0
11	Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine. Current Pharmaceutical Design, 2021, 27, 3293-3304.	1.9	13
12	Expert opinion in panic disorder: The impact of COVID-19-related fears, protective devices, and lockdown on panic and agoraphobia. Personalized Medicine in Psychiatry, 2021, 27-28, 100080.	0.1	1
13	Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health. Personalized Medicine in Psychiatry, 2021, 27-28, 100077.	0.1	0
14	Oxidative Stress in the Early Stage of Psychosis. Current Topics in Medicinal Chemistry, 2021, 21, 1457-1470.	2.1	6
15	Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive-compulsive disorder. Journal of Psychosomatic Research, 2021, 150, 110604.	2.6	6
16	Can personalized medicine mitigate confirmation bias in mental health?. Revista Brasileira De Psiquiatria, 2021, , .	1.7	0
17	Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice. Microbial Biotechnology, 2020, 14, 336-342.	1.7	30
18	Heart rate variability: Can it serve as a marker of mental health resilience?. Journal of Affective Disorders, 2020, 263, 754-761.	4.1	71

#	ARTICLE	IF	CITATIONS
19	Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday “real world” clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 83-87.	2.4	36
20	Impact of respiratory protective devices on respiration: Implications for panic vulnerability during the COVID-19 pandemic.. <i>Journal of Affective Disorders</i> , 2020, 277, 772-778.	4.1	20
21	The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3619.	2.4	3
22	“Precision” or “personalized” psychiatry: different terms “ same content?”. <i>Fortschritte Der Neurologie Psychiatrie</i> , 2020, 88, 759-766.	0.5	3
23	Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-Episode Major Depression: An Exploratory Study in the Real World Clinical Practice. <i>Brain Sciences</i> , 2020, 10, 912.	2.3	19
24	Relapse prevention in panic disorder with pharmacotherapy: where are we now?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1699-1711.	1.8	8
25	Personalized Clinical Approaches to Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 489-521.	1.6	9
26	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 317-321.	1.7	14
27	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 554-584.	2.1	25
28	Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables. <i>Psychiatry Investigation</i> , 2020, 17, 193-206.	1.6	23
29	A Novel Ensemble-Based Machine Learning Algorithm to Predict the Conversion From Mild Cognitive Impairment to Alzheimer's Disease Using Socio-Demographic Characteristics, Clinical Information, and Neuropsychological Measures. <i>Frontiers in Neurology</i> , 2019, 10, 756.	2.4	68
30	<p>Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1957-1970.	2.2	10
31	Common and different neural markers in major depression and anxiety disorders: A pilot structural magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 290, 42-50.	1.8	35
32	The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. <i>Frontiers in Psychiatry</i> , 2019, 10, 294.	2.6	50
33	When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia. , 2019, , 349-367.		3
34	A clinically-translatable machine learning algorithm for the prediction of Alzheimer’s disease conversion: further evidence of its accuracy via a transfer learning approach. <i>International Psychogeriatrics</i> , 2019, 31, 937-945.	1.0	28
35	The role of spatial store and executive strategy in spatial working memory: a comparison between patients with obsessive-compulsive disorder and controls. <i>Cognitive Neuropsychiatry</i> , 2019, 24, 14-27.	1.3	2
36	Mental health professionals’ attitudes towards mental illness: professional and cultural factors in the INTER NOS study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 325-339.	3.2	27

#	ARTICLE	IF	CITATIONS
37	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. Current Pharmaceutical Design, 2019, 25, 381-387.	1.9	33
38	Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry Investigation, 2019, 16, 50-58.	1.6	16
39	Neuroprogression in anxiety disorders. , 2019, , 129-146.		0
40	A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1555-1573.	2.6	52
41	Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Advances in Drug Safety, 2018, 9, 237-256.	2.4	130
42	Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective. Expert Opinion on Drug Discovery, 2018, 13, 221-228.	5.0	12
43	Atypical Antipsychotics in Major Depressive Disorder. , 2018, , 257-268.		2
44	Precision Psychiatry: Personalized Clinical Approach to Depression. , 2018, , 245-261.		0
45	Personality biomarkers of pathological gambling: A machine learning study. Journal of Neuroscience Methods, 2018, 294, 7-14.	2.5	14
46	The revolution of personalized psychiatry: will technology make it happen sooner?. Psychological Medicine, 2018, 48, 705-713.	4.5	77
47	Features of mood associated with high body weight in females with fibromyalgia. Comprehensive Psychiatry, 2018, 80, 57-64.	3.1	8
48	Reduced cortical thickness and increased gyrification in generalized anxiety disorder: a 3 T MRI study. Psychological Medicine, 2018, 48, 2001-2010.	4.5	45
49	Is panic disorder a disorder of physical fitness? A heuristic proposal. F1000Research, 2018, 7, 294.	1.6	13
50	Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors. International Journal of Molecular Sciences, 2018, 19, 2888.	4.1	137
51	Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years. Expert Opinion on Pharmacotherapy, 2018, 19, 1357-1368.	1.8	13
52	Commentary: Cognitive Behavioral Therapy vs. Eye Movement Desensitization and Reprocessing for Treating Panic Disorder: A Randomized Controlled Trial. Frontiers in Psychology, 2018, 9, 1061.	2.1	2
53	Controlled-release pregabalin in the treatment of fibromyalgia. Expert Review of Neurotherapeutics, 2018, 18, 617-623.	2.8	4
54	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. Current Neuropharmacology, 2018, 16, 583-606.	2.9	72

#	ARTICLE	IF	CITATIONS
55	Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder. Archives of Suicide Research, 2017, 21, 100-112.	2.3	46
56	Mediation effect of recent loss events on weight gain in obese people who experienced childhood parental death or separation. Journal of Health Psychology, 2017, 22, 101-110.	2.3	2
57	Personalized Medicine in Psychiatry: Back to the Future. Personalized Medicine in Psychiatry, 2017, 1-2, 1.	0.1	8
58	Latent classes of emotional and behavioural problems in epidemiological and referred samples and their relations to DSM-IV diagnoses. European Child and Adolescent Psychiatry, 2017, 26, 549-557.	4.7	25
59	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. CNS Spectrums, 2017, 22, 342-347.	1.2	43
60	Personalized medicine in panic disorder: where are we now? A meta-regression analysis. Personalized Medicine in Psychiatry, 2017, 1-2, 26-38.	0.1	5
61	Management of Treatment-Resistant Panic Disorder. Current Treatment Options in Psychiatry, 2017, 4, 371-386.	1.9	22
62	Does gender influence cognitive function in non-psychotic depression?. Personalized Medicine in Psychiatry, 2017, 4-6, 25-31.	0.1	3
63	The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. International Review of Psychiatry, 2017, 29, 425-435.	2.8	31
64	Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review. Frontiers in Psychiatry, 2017, 8, 148.	2.6	118
65	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. International Journal of Molecular Sciences, 2017, 18, 349.	4.1	30
66	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Research International, 2017, 2017, 1-17.	1.9	23
67	Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?. Minerva Psychiatry, 2017, 58, .	0.3	1
68	Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes. Psychiatry Investigation, 2017, 14, 8.	1.6	3
69	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. CNS and Neurological Disorders - Drug Targets, 2017, 16, 65-92.	1.4	25
70	Childhood adversities in patients with fibromyalgia: are they related to comorbid lifetime major depression?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 105, 112-118.	0.8	4
71	Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders. , 2016, , 305-316.		0
72	Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 1827-1836.	2.2	21

#	ARTICLE	IF	CITATIONS
73	Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines. International Journal of Molecular Sciences, 2016, 17, 551.	4.1	17
74	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatric Disease and Treatment, 2016, 12, 719.	2.2	74
75	Does the "Silver Bullet" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. Clinical Practice and Epidemiology in Mental Health, 2016, 12, 142-157.	1.2	12
76	Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression. Neural Plasticity, 2016, 2016, 1-19.	2.2	64
77	Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials. International Journal of Molecular Sciences, 2016, 17, 241.	4.1	43
78	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. Frontiers in Psychiatry, 2016, 7, 138.	2.6	115
79	A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.. CNS and Neurological Disorders - Drug Targets, 2016, 15, 35-44.	1.4	53
80	Comments on "Heart rate and respiratory response to doxapram in patients with panic disorder". Psychiatry Research, 2016, 239, 362-363.	3.3	1
81	Role of worry in patients with chronic tinnitus and sensorineural hearing loss: a preliminary study. European Archives of Oto-Rhino-Laryngology, 2016, 273, 4145-4151.	1.6	7
82	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics, 2016, 16, 483-495.	2.8	18
83	Psychiatric Disorders and Childhood Parental Loss in Obesity: Relationship with the Mode of Weight Gain. Journal of Loss and Trauma, 2016, 21, 213-224.	1.5	4
84	Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study. International Journal of Psychiatry in Clinical Practice, 2016, 20, 224-231.	2.4	7
85	Inflammatory markers and suicidal attempts in depressed patients: A review. International Journal of Immunopathology and Pharmacology, 2016, 29, 583-594.	2.1	27
86	An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety, 2016, 15, 1329-1347.	2.4	112
87	Is there cardiac risk in panic disorder? An updated systematic review. Journal of Affective Disorders, 2016, 194, 38-49.	4.1	24
88	The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology, 2016, 63, 327-342.	2.7	273
89	The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis. Journal of Affective Disorders, 2016, 195, 105-118.	4.1	92
90	Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Current Psychiatry Reports, 2016, 18, 23.	4.5	50

#	ARTICLE	IF	CITATIONS
91	Effect of family structure and TPH2 G-703T on the stability of dysregulation profile throughout adolescence. <i>Journal of Affective Disorders</i> , 2016, 190, 576-584.	4.1	7
92	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2016, 22, 5144-5162.	1.9	25
93	S-Adenosyl-L-Methionine for Major Depressive Disorder. , 2016, , 847-854.		0
94	Alexithymia and Breast Cancer Surgery: A Systematic Review. <i>British Journal of Medicine and Medical Research</i> , 2016, 15, 1-11.	0.2	1
95	Panic Disorder, Is It Really a Mental Disorder? From Body Functions to the Homeostatic Brain. , 2016, , 93-112.		0
96	Is panic disorder associated with clinical severity of fibromyalgia? A preliminary study in a tertiary-care centre. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S99-105.	0.8	1
97	Novel investigational therapeutics for panic disorder. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 491-505.	4.1	30
98	Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1111-1130.	4.1	66
99	Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study. <i>Comprehensive Psychiatry</i> , 2015, 58, 82-87.	3.1	36
100	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). <i>Journal of Affective Disorders</i> , 2015, 178, 112-120.	4.1	14
101	Is there a role for pharmacogenetics in the treatment of panic disorder?. <i>Pharmacogenomics</i> , 2015, 16, 771-774.	1.3	7
102	Prevalence and clinical features associated to bipolar disorderâ€migraine comorbidity: a systematic review. <i>Comprehensive Psychiatry</i> , 2015, 56, 1-16.	3.1	20
103	Laboratory, Clinical and Therapeutic Features of Respiratory Panic Disorder Subtype. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 627-635.	1.4	18
104	Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2014, 8, 30-37.	0.6	24
105	Effect of the serotonin transporter gene and of environment on the continuity of anxiety and depression traits throughout adolescence. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 399-409.	3.9	8
106	Childhood Trauma, Temperament, and Character in Subjects With Major Depressive Disorder and Bipolar Disorder. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 695-698.	1.0	14
107	Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 125-130.	1.7	50
108	Are Respiratory Abnormalities Specific for Panic Disorder? A Meta-Analysis. <i>Neuropsychobiology</i> , 2014, 70, 52-60.	1.9	31



#	ARTICLE	IF	CITATIONS
109	Self-reported quality of life and clinician-rated functioning in mood and anxiety disorders: Relationships and neuropsychological correlates. <i>Comprehensive Psychiatry</i> , 2014, 55, 979-988.	3.1	13
110	Panic and the Brainstem: Clues from Neuroimaging Studies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1049-1056.	1.4	20
111	Baseline respiratory parameters in panic disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2013, 146, 158-173.	4.1	56
112	Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone. <i>Acta Neuropsychiatrica</i> , 2013, 25, 119-121.	2.1	3
113	The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12458-12483.	4.1	66
114	Insomnia as a predictor of high-lethality suicide attempts. <i>International Journal of Clinical Practice</i> , 2013, 67, 1311-1316.	1.7	83
115	S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study. <i>Scientific World Journal</i> , The, 2013, 2013, 1-5.	2.1	20
116	Understanding anxiety disorders: the psychology and the psychopathology of defence mechanisms against threats. <i>Rivista Di Psichiatria</i> , 2013, 48, 73-5.	0.6	8
117	Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review. <i>Current Clinical Pharmacology</i> , 2013, 8, 256-264.	0.6	25
118	Effects of Cigarette Smoking on Neuropsychological Performance in Mood Disorders. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e130-e136.	2.2	21
119	The Relationships between Cholesterol and Suicide: An Update. , 2012, 2012, 1-6.		54
120	Temperament, Character and Anxiety Sensitivity in Panic Disorder: A High-Risk Study. <i>Psychopathology</i> , 2012, 45, 300-304.	1.5	5
121	The somatic marker affecting decisional processes in obsessive-compulsive disorder. <i>Cognitive Neuropsychiatry</i> , 2012, 17, 177-190.	1.3	34
122	Emerging drugs for panic disorder. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 631-645.	2.4	21
123	Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines. <i>Neuropsychobiology</i> , 2011, 63, 1-7.	1.9	20
124	Is there a hypersensitive visual alarm system in panic disorder?. <i>Psychiatry Research</i> , 2011, 187, 387-391.	3.3	29
125	Cardiorespiratory response to physical exercise and psychological variables in panic disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 385-389.	1.7	11
126	Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 621.	2.2	11



#	ARTICLE	IF	CITATIONS
127	Tradução e adaptação transcultural do Questionário de Atividade Física Habitual. Revista De Psiquiatria Clinica, 2010, 37, 16-22.	0.6	18
128	Dizziness, migrainous vertigo and psychiatric disorders. Journal of Laryngology and Otology, 2010, 124, 285-290.	0.8	29
129	Panic Disorder Respiratory Subtype: Psychopathology, Laboratory Challenge Tests, and Response to Treatment. Harvard Review of Psychiatry, 2010, 18, 220-229.	2.1	65
130	Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder patients. World Journal of Biological Psychiatry, 2010, 11, 357-363.	2.6	9
131	Acoustic startle response in panic disorder. Psychiatry Research, 2010, 176, 254-256.	3.3	7
132	Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opinion on Pharmacotherapy, 2010, 11, 1167-1181.	1.8	21
133	Freezing reaction in panic disorder patients associated with anticipatory anxiety. Depression and Anxiety, 2009, 26, 917-921.	4.1	41
134	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 1-18.	1.7	42
135	Clonazepam in the treatment of psychiatric disorders: an update. International Clinical Psychopharmacology, 2006, 21, 131-142.	1.7	41
136	Anxiety Sensitivity in Children of Panic Disorder Patients. Child Psychiatry and Human Development, 2005, 35, 315-324.	1.9	15
137	Antipanic Efficacy of Paroxetine and Polymorphism within the Promoter of the Serotonin Transporter Gene. Neuropsychopharmacology, 2005, 30, 2230-2235.	5.4	93
138	Comparison of the Treatment with Paroxetine and Reboxetine in Panic Disorder: A Randomized, Single-Blind Study. Pharmacopsychiatry, 2004, 37, 206-210.	3.3	43
139	Panic disorder: from respiration to the homeostatic brain. Acta Neuropsychiatrica, 2004, 16, 57-67.	2.1	55
140	Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. American Journal of Medical Genetics Part A, 2004, 129B, 41-43.	2.4	18
141	Language of dyspnea in panic disorder. Depression and Anxiety, 2004, 20, 32-38.	4.1	35
142	Selective serotonin re-uptake inhibitors beyond psychiatry: Are they useful in the treatment of severe, chronic, obstructive pulmonary disease?. Depression and Anxiety, 2004, 20, 203-204.	4.1	16
143	Smoking and respiratory irregularity in panic disorder. Biological Psychiatry, 2004, 56, 393-398.	1.3	30
144	Comparison of 35% carbon dioxide reactivity between panic disorder and eating disorder. Psychiatry Research, 2004, 125, 277-283.	3.3	20

#	ARTICLE	IF	CITATIONS
145	Anxiety sensitivity and modulation of the serotonergic system in patients with PD. Journal of Anxiety Disorders, 2004, 18, 423-431.	3.2	12
146	Approximate Entropy of Respiratory Patterns in Panic Disorder. American Journal of Psychiatry, 2004, 161, 79-87.	7.2	112
147	Modulation of Hyperreactivity to 35% CO2 After One Week of Treatment With Paroxetine and Reboxetine. Journal of Clinical Psychopharmacology, 2004, 24, 277-282.	1.4	32
148	Serotonergic modulation of the balance system in panic disorder: An open study. Depression and Anxiety, 2003, 17, 101-106.	4.1	26
149	Anxiety sensitivity and 35% CO2 reactivity in patients with panic disorder. Journal of Psychosomatic Research, 2003, 54, 573-577.	2.6	24
150	Neurosteroid secretion in panic disorder. Psychiatry Research, 2003, 118, 107-116.	3.3	107
151	Vulnerability to 35% CO2 of panic disorder patients with a history of respiratory disorders. Psychiatry Research, 2003, 120, 125-130.	3.3	13
152	Pregnancy and Respiratory Nocturnal Panic Attacks. Canadian Journal of Psychiatry, 2003, 48, 573-574.	1.9	3
153	The Effect of One-Week Treatment with Venlafaxine on 35% CO2 Hyperreactivity in Patients with Panic Disorder: An Open Study. Journal of Clinical Psychopharmacology, 2003, 23, 106-108.	1.4	8
154	Antipanic Drug Modulation Of 35% CO2 Hyperreactivity and Short-Term Treatment Outcome. Journal of Clinical Psychopharmacology, 2002, 22, 300-308.	1.4	44
155	Respiration in Children at Risk for Panic Disorder. Archives of General Psychiatry, 2002, 59, 185.	12.3	26
156	The 35% CO2 Hyperreactivity and Clinical Symptomatology in Patients With Panic Disorder After 1 Week of Treatment With Citalopram: An Open Study. Journal of Clinical Psychopharmacology, 2001, 21, 262-267.	1.4	31
157	Panic disorder: the role of the balance system. Journal of Psychiatric Research, 2001, 35, 279-286.	3.1	76
158	A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study. Pharmacopsychiatry, 2001, 34, 85-90.	3.3	62
159	Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation. Psychoneuroendocrinology, 2000, 25, 301-310.	2.7	22
160	Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. Psychiatry Research, 1999, 89, 21-27.	3.3	25
161	A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO2 challenge. Biological Psychiatry, 1999, 45, 365-367.	1.3	27
162	A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge. Biological Psychiatry, 1999, 46, 815-820.	1.3	29

#	ARTICLE	IF	CITATIONS
163	Sensitivity to 35% Carbon Dioxide in Patients With Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 1999, 60, 379-384.	2.2	41
164	PLASMA CONCENTRATIONS OF INTERLEUKIN-1 $\beta$ , INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR- $\alpha$ IN ANOREXIA AND BULIMIA NERVOSA. Psychoneuroendocrinology, 1998, 23, 439-447.	2.7	37
165	Growth hormone response to growth hormone-releasing hormone stimulation in obsessive-compulsive disorder. Psychiatry Research, 1998, 81, 293-299.	3.3	4
166	CO <sub>2</sub> -Induced Panic Attacks: A Twin Study. American Journal of Psychiatry, 1998, 155, 1184-1188.	7.2	86
167	CO <sub>2</sub> challenge in nonclinical subjects. American Journal of Psychiatry, 1997, 154, 886-887.	7.2	7
168	Asthma and panic attacks. Biological Psychiatry, 1997, 42, 625-630.	1.3	83
169	Plasma Interleukin-1 $\beta$ and Tumor Necrosis Factor Concentrations in Obsessive-Compulsive Disorders. Biological Psychiatry, 1997, 42, 976-981.	1.3	61
170	Dopamine function in obsessive-compulsive disorder: Growth hormone response to apomorphine stimulation. Biological Psychiatry, 1997, 42, 889-897.	1.3	45
171	Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration. Psychiatry Research, 1997, 69, 163-168.	3.3	14
172	Noradrenergic receptor sensitivity in obsessive-compulsive disorders: I. growth hormone response to clonidine stimulation. Psychiatry Research, 1997, 69, 155-162.	3.3	18
173	The 35% CO <sub>2</sub> challenge test in patients with social phobia. Psychiatry Research, 1997, 71, 41-48.	3.3	76
174	Panic attacks: a twin study. Psychiatry Research, 1997, 66, 69-71.	3.3	54
175	Pharmacologic Effect of Imipramine, Paroxetine, and Sertraline on 35% Carbon Dioxide Hypersensitivity in Panic Patients. Journal of Clinical Psychopharmacology, 1997, 17, 97-101.	1.4	53
176	Modification of 35% Carbon Dioxide Hypersensitivity Across One Week of Treatment With Clomipramine and Fluvoxamine. Journal of Clinical Psychopharmacology, 1997, 17, 173-178.	1.4	45
177	Family history of panic disorder and hypersensitivity to CO <sub>2</sub> in patients with panic disorder. American Journal of Psychiatry, 1996, 153, 1060-1064.	7.2	71
178	Citalopram and panic disorder. , 1996, 4, 253-253.		0
179	$\beta$ -Adrenergic receptor sensitivity in panic disorder: I. Psychoneuroendocrinology, 1995, 20, 1-9.	2.7	36
180	$\beta$ -Adrenergic receptor sensitivity in panic disorder: II. Psychoneuroendocrinology, 1995, 20, 11-19.	2.7	21

#	ARTICLE	IF	CITATIONS
181	The 35% CO <sub>2</sub> challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis. <i>Journal of Psychiatric Research</i> , 1995, 29, 111-119.	3.1	96
182	Menstrual cycle-related sensitivity to 35% CO <sub>2</sub> in panic patients. <i>Biological Psychiatry</i> , 1995, 37, 528-532.	1.3	46
183	T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. <i>Psychiatry Research</i> , 1995, 59, 43-50.	3.3	23
184	T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa. <i>Psychiatry Research</i> , 1995, 59, 51-56.	3.3	18
185	Hypersensitivity to inhalation of carbon dioxide and panic attacks. <i>Psychiatry Research</i> , 1995, 57, 267-273.	3.3	63
186	35% CO <sub>2</sub> challenge in panic and mood disorders. <i>Journal of Affective Disorders</i> , 1995, 33, 189-194.	4.1	84
187	Alpha-2-Adrenoceptor Sensitivity in Heroin Addicts with and without Previous Attention Deficit Disorder/Hyperactivity and Conduct Disorder. <i>Neuropsychobiology</i> , 1994, 30, 15-19.	1.9	18
188	Subclinical impairment of lung airways in patients with panic disorder. <i>Biological Psychiatry</i> , 1994, 36, 601-605.	1.3	18
189	Plasma interleukin-1 beta concentrations in panic disorder. <i>Psychiatry Research</i> , 1994, 54, 135-142.	3.3	54
190	Carbon dioxide/oxygen challenge test in panic disorder. <i>Psychiatry Research</i> , 1994, 52, 159-171.	3.3	145
191	Pharmacologic Effect of Toloxatone on Reactivity to the 35% Carbon Dioxide Challenge. <i>Journal of Clinical Psychopharmacology</i> , 1994, 14, 414-418.	1.4	24
192	Prevalence of respiratory diseases in patients with panic and obsessive compulsive disorders. <i>Anxiety</i> , 1994, 1, 100-101.	0.4	11
193	DSM-III-R personality disorders in panic disorder. <i>Journal of Anxiety Disorders</i> , 1993, 7, 153-161.	3.2	12
194	Psychoimmunoendocrine Aspects of Panic Disorder. <i>Neuropsychobiology</i> , 1992, 26, 12-22.	1.9	68
195	DSM-III-R personality disorders in panic and obsessive-compulsive disorder: A comparison study. <i>Comprehensive Psychiatry</i> , 1991, 32, 450-457.	3.1	36
196	Respiration and Anxiety. , 0, , 251-267.		1
197	Anxiety, depression, and suicide: epidemiology, pathophysiology, and prevention. , 0, , 93-100.		2
198	The role of melatonin in mood disorders. <i>ChronoPhysiology and Therapy</i> , 0, , 65.	0.5	11

#	ARTICLE	IF	CITATIONS
199	The “Emotional Side” of Subjective Tinnitus. , 0, , .		1